Background

Percepta® is a patent-protected brain health natural dietary supplement (active ingredients, PTI-00703® Cat’s claw and MemorTea® - a specific oolong tea extract). Cerebrum DAO will be supporting the development of near- and long-term solutions for targeting cognitive decline, memory loss and neurodegenerative diseases.

Percepta® has the potential to be the category leader in this fast growing $8.6b market with human evidence to support outcomes and the funding of future studies that could lead to FDA botanical drug status which is the ultimate goal.

This IPT represents a world’s first tokenization of a robust patent portfolio and a world’s first tokenized crowdsale for a clinical evidence study.

Commercial Potential

Grand View Research determined the global brain health supplements market was valued at $8.6 billion in 2022 and is expected to grow at a CAGR of 13.3% from 2023 to 2030. The growth is attributed to rising awareness of issues, such as lack of attention, focus, declining memory, anxiety, and depression. The increasing adoption of natural and herbal health products is anticipated to fuel the industry's growth over the forecast period.

Existing solutions lack evidence to support true outcomes in humans. Prevagen is a leading memory support supplement with annual revenues that exceed $200 million per year, yet the product is promoted largely with anecdotal quotes from users.

Milestones & Agreements

Milestone 1: Research organization contracting for replication study

CRO contract with Reputable Health to conduct decentralized trial with Percepta® materials for study.

Required Funding: $245,000 ($182,000 for CRO + $63,000 for Percepta® production costs)
Duration: 10 Months

Milestone 2: Contract research lab for in vitro study

In vitro testing.

Required Funding: $10,000
Duration: 1 Month

Cognitive Clarity IP license

License to Cognitive Clarity patent portfolio and royalty.

Required Funding: On contract execution $100,000
Duration: Immediate

Percepta® materials for study

Production costs of Percepta® required for the study.

Required Funding: On contract execution $63,000
‍Duration: Immediate

Senior Review

The primary research for Percepta® is based on the work of Dr. Alan Snow, who also leads its commercialization. In vitro and animal studies show promising results, including reduced brain plaque and improved memory in rodent models. Key ingredients like PTI-777, derived from Uncaria tomentosa (cat’s claw), cross the blood-brain barrier and demonstrate strong effects on plaque reduction and inflammation. Additional support comes from broader literature on polyphenols, including studies with grape seed extract, showing cognitive benefits in animal models. Human data is more limited; while some studies involving cat’s claw-containing supplements suggest cognitive improvements, results are mixed and often involve multiple active ingredients. Overall, reviewers recognize the strong preclinical foundation and support the project, noting that further human studies will strengthen the case.